Clinical trial
Sitagliptin Phosphate/Metformin HCl (JANUMET®) Post Marketing Surveillance Protocol
NCT01357148 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Sitagliptin Phosphate/Metformin HCl (JANUMET®) Post Marketing Surveillance Protocol
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Observational
- Overall status
- Terminated
- Start date
- March 31, 2009
- Completion date
- May 31, 2010
- Enrollment
- 143 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.